Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Pipeline

Home

Contact

Values

Board

Company Overview

Team

Corporate Governance

Corporate Directory

Clinical Advisers

About Us

Video Updates

Presentations

In the News

Communication

Updates

US Shareholders

Investor FAQs

Shareholder Services

Research Reports

Reports

Announcements

Investor Fact Sheet

Top 20 Shareholders

Share Price

Investor Centre

Clinical Trial

Webinars

Montserrat

Amplia Therapeutics Limited

Amplia is pleased to announce that it has that the United States Food and Drug Administration (FDA) has granted Fast Track Designation the Company’s Focal Adhesion Kinase inhibitor, narmafotinib, for the treatment of advanced pancreatic cancer.

Fast Track Designation facilitates the development of investigational drugs and allows for expedited review. It is available to drugs that provide an advantage over current therapies that treat serious conditions and is designed to get these drugs to patients earlier. This Designation will grant the Company access to more frequent meetings, and written communication, with the FDA.

Amplia CEO and MD, Dr Chris Burns, commented:

“Fast Track Designation for narmafotinib is a significant milestone for the Company. With this designation, we can work more closely with the FDA to accelerate our clinical program and gather the most compelling evidence for regulatory approval in this devastating disease.”

FDA Fast Track Designation Granted to Narmafotinib in Pancreatic Cancer